Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialPubMedOpen access

Single-cell transcriptomic analysis reveals therapeutic mechanisms of adipose-derived stem cell exosomes in sepsis-induced lung injury.

Wu SC., Rau CS., Wu YC., Lin CW., Lu TH., Tsai CW.

Randomized Controlled Trial with a reported sample of 12 on Chronic Inflammation, published in Int J Surg (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Int J Surg (2025)
Country
United States
Reported sample size
12
Source database
PubMed
PMID
40607951
PMCID
PMC12695251
DOI
10.1097/JS9.0000000000002894
Citations
2

Abstract (original English)

Background Sepsis-induced acute lung injury remains a leading cause of mortality in critically ill patients, with limited effective treatments beyond supportive care. This study investigates the therapeutic efficacy and underlying mechanisms of adipose-derived stem cell (ADSC) exosomes on sepsis-induced lung injury and characterizes underlying cellular and molecular mechanisms. Methods We employed a cecal ligation and puncture (CLP) mouse model of sepsis and using male C57BL/6J mice ( Mus musculus , 8-10 weeks old) and administered ADSC-derived exosomes intravenously. Animals were randomly assigned to Sham, CLP, or CLP + ADSC-exosome groups. Survival rates ( n =12 for each group) and lung histopathology ( n =5 for each group) were assessed. Single-cell RNA sequencing was performed on lung tissues to analyze cell type-specific transcriptomic changes and intercellular communication networks ( n =2 for each group). Results ADSC exosome treatment significantly improved survival rates and reduced lung pathology in CLP mice. Treatment altered lung cellular composition, increasing neutrophils, NKT cells, and monocytes while decreasing B and T cells. Gene expression analysis revealed downregulation of pro-inflammatory markers (TNF, IL-10, CCL3, and CCL4) and upregulation of tissue repair pathways. In neutrophils, exosomes reduced expression of respiratory burst genes while enhancing ti

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AnimalsExosomesSepsisMice, Inbred C57BLMaleMiceAcute Lung InjuryDisease Models, AnimalSingle-Cell AnalysisGene Expression Profiling

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research